Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merck & Co., Inc. < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting May 15, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Participate in Bank of America Securities 2023 Healthcare Conference May 03, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer April 28, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces First-Quarter 2023 Financial Results April 27, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer April 16, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. April 16, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK RXDX FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma April 13, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017) April 07, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer April 03, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27 March 30, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors March 29, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status March 27, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) March 16, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma March 10, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present at the Barclays 2023 Global Healthcare Conference March 08, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy March 06, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study March 06, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) March 06, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer March 02, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer March 01, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789 February 28, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir) February 24, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection February 22, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline February 21, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19 February 21, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk February 17, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression February 16, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium February 16, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma February 03, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results February 02, 2023 From Merck & Co., Inc. Via Business Wire Tickers MRK < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.